News
New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...
Panelists discuss how the unprecedented 5-year progression-free survival benefit (60% vs 8%) demonstrated in the CROWN trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback